| 1.7 -0.2 (-10.53%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.7 | 1-year : | 3.62 |
| Resists | First : | 2.31 | Second : | 3.09 |
| Pivot price | 1.89  |
|||
| Supports | First : | 1.04 | Second : | 0.87 |
| MAs | MA(5) : | 2 |
MA(20) : | 1.74 |
| MA(100) : | 1.63 |
MA(250) : | 3.53 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 38.6 |
D(3) : | 46 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 14 | Low : | 0.76 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ADIL ] has closed above bottom band by 41.7%. Bollinger Bands are 125.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.88 - 1.89 | 1.89 - 1.9 |
| Low: | 1.63 - 1.64 | 1.64 - 1.66 |
| Close: | 1.68 - 1.7 | 1.7 - 1.72 |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Mon, 22 Apr 2024
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent - Yahoo Canada Finance
Mon, 22 Apr 2024
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office - Yahoo Finance Australia
Tue, 16 Apr 2024
Adial Pharmaceuticals Announces CMO's Departure and Leadership Changes - TipRanks.com - TipRanks
Fri, 12 Apr 2024
Adial Pharmaceuticals files to sell 2.37M common shares for holders (NASDAQ:ADIL) - Seeking Alpha
Wed, 10 Apr 2024
MSTR, ADIL, ALPN, MRIN, TSLA: Top 5 Trending Stocks Today - Adial Pharmaceuticals (NASDAQ:ADIL) - Benzinga
Wed, 10 Apr 2024
Adial Pharmaceuticals posts promising update on alcohol disorder drug - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 28 (K) |
| EPS | -4.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.45 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -82.3 % |
| Return on Equity (ttm) | -190.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.35 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|